Several methodologies for evaluating the antifungal susceptibility of Cryptococcus neoformans have been proposed, but only three are included in the National Committee for Clinical Laboratory Standards (NCCLS) M27A document (1, 4, 9). The NCCLS standard recommends the use of RPMI 1640 buffered to a pH of 7.0 as the medium for testing by either the macrodilution or the microdilution method and an initial inoculum size of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 (4). As Cryptococcus neoformans grows slowly in liquid culture medium, an incubation period of 70 to 74 h at 35°C was recommended (4). Ghannoum et al. (1) advise the use of a microdilution method with buffered yeast nitrogen base (BYNB) medium (pH 7.0), a higher inoculum size (10 4 CFU/ml), and a spectrophotometric determination of a 50% inhibition endpoint; this is an alternative method outlined in the M27A document.
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Odds et al. (5) demonstrated that oxygen is a limiting factor for C. neoformans grown in liquid media, and they recommended cultivation under constant agitation. Others reported (6, 9, 10) that RPMI 1640 with 2% glucose supported better growth of yeasts than RPMI 1640 alone. The purpose of this study is to compare the NCCLS M27A, BYNB, and RPMI-2% glucose methodologies (1, 4, 9) in static versus agitated microtiter plates to ascertain the influence of agitation in C. neoformans growth and minimum inhibitory concentration (MIC) determination.
Organisms. A collection of 35 C. neoformans isolates was included. A total of 27 were clinical isolates obtained from blood cultures or cerebrospinal fluid. A total of 15 were obtained from 15 Argentinean AIDS patients with cryptococcal meningitis, of whom 10 responded to treatment with 0.7 mg of amphotericin B/kg of body weight/day and could be classified as putatively susceptible, while 5 failed to respond clinically to 0.7 mg of amphotericin B/kg/day and could be considered putatively resistant. Two subjects died within 24 to 48 h of treatment, while the remaining three died despite a cumulative dose of 500 mg of amphotericin B. Six strains (CN5, CN6, CN7, CN8, CN10, and CN12) were kindly provided by John Rex (University of Texas Medical School). CN5 and CN8 are considered to be amphotericin B susceptible and resistant, respectively, based on clinical observations (7) . Isolates CN6 and CN7 were from AIDS patients with cryptococcal meningitis who were responsive to amphotericin B treatment (2) . CN10 and CN12 were from an Australian human immunodeficiency virus-infected patient who developed resistance during treatment (D. J. E. Marriot, R. Hardiman, S. Chen, J. L. Harkness, and R. Pennry, 3rd Int. Conf. Cryptococcus Cryptococcosis, abstr. 3.21, 1996) . C. neoformans ATCC 90112 (3), C. neoformans CNML3405, and Candida albicans ATCC 64548 (8) were included as internal control strains. The quality control (QC) strains, Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 (4), were also included in all experiments.
Antifungal agents. The antifungal agents used in the study were as follows: amphotericin B (Sigma Aldrich Quimica, S.A., Madrid, Spain), flucytosine (Sigma Aldrich Quimica, S.A.), fluconazole (Pfizer S.A., Madrid, Spain), and itraconazole (Janssen S.A., Madrid, Spain). Amphotericin B, fluconazole, and itraconazole were dissolved in 100% dimethyl sulfoxide (Sigma Aldrich Quimica, S.A.). Flucytosine was dissolved in sterile distilled water. All drug stock solutions were frozen at Ϫ70°C as 100ϫ stocks until used. The procedure rigorously followed the instructions designed by Ghannoum et al., using BYNB and yeast inoculum size of 10 4 CFU/ml (1). The final ranges of antifungal concentrations were as follows: amphotericin B, from 8 to 0.015 g/ml; flucytosine and fluconazole, from 64 to 0.12 g/ml; and itraconazole, from 4 to 0.007 g/ml. All microplates were incubated at 35°C for 48 h. One set of microplates was wrapped with film sealer to prevent the medium from evaporating, attached to an electrically driven wheel inside the incubator, and agitated at 350 rpm. A corresponding set was incubated statically with their corresponding plastic covers. Madrid, Spain). After the incubation, the microplates were mechanically agitated at 1,400 rpm for 30 s inside the plate reader and then read. The mean A 540 of eight blank wells (column 12) was subtracted from the absorbance value obtained from each well. Two MIC endpoints were defined as follows: (i) the lowest drug concentration exhibiting reduction in growth of 80% or more compared with that of the control growth as recommended by NCCLS M27A for macrodilution (4) (MIC 80 ) and (ii) the lowest drug concentration exhibiting a reduction in growth of 50% or more compared with that of the control growth as recommended by Ghannoum et al. for C. neoformans (1) (MIC 50 ). Only MIC 80 of amphotericin B was calculated, while both the MIC 80 s and the MIC 50 s of flucytosine and the azoles were determined.
Growth curves. The growth curves for 16 of the 35 C. neoformans isolates and the control strains C. albicans ATCC 64548, C. parapsilosis ATCC 22019, and C. krusei ATCC 6258 were determined by using the microdilution format. The final yeast inoculum was approximately 10 5 CFU/ml. The microplates were incubated for 48 h at 35°C inside a plate set at a wavelength of 540 nm with agitation at 1,400 rpm (5 min of agitation, 5 min stopped) or statically. All procedures were repeated with three different inoculum preparations.
Statistical analysis. The A 540 in the growth control well must be Ͼ0.09 U to calculate the spectrophotometric MIC 80 For agitated cultures, the best growth was obtained with BYNB (inoculum size, 10 4 CFU/ml) followed by RPMI-2% glucose (inoculum size, 0.5 ϫ 10 5 to 2.5 ϫ 10 5 CFU/ml). Again, the NCCLS M27A methodology (RPMI 1640, inoculum size of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml) yielded poorer growth. The CI95% for the 33 C. neoformans isolates growing in agitated microplates was very narrow in RPMI-2% glucose, thus showing good reproducibility growth. All isolates reached A 540 values of Ն0.24 U (Table 1) . With BYNB, one isolate did not reach an A 540 of 0.2 U and the CI95% was 0.41 to 0.5 U. With the NCCLS M27A method, 57.6% of the isolates did not attain an A 540 of Ͼ0.199 U.
(ii) Growth curves. The results obtained with the antifungal susceptibility testing suggested that the size of inoculum could have a great influence on the C. neoformans growth. For this reason, we designed the growth curve experiments with the same starting inoculum size of 10 5 CFU/ml. Figure 1 shows the mean A 540 values of 16 individual growth curves generated for 16 C. neoformans isolates in each medium. Despite an inoculum size of 10 5 CFU/ml, the growth in static cultures was very poor compared to growth in agitated cultures. The highest A 540 values (mean Ϯ SD) reached in each medium at 48 h of incubation were as follows: RPMI 1640, 0.13 Ϯ 0.03 U (CI95%, 0.10 to 0.15 U); RPMI-2% glucose, 0.15 Ϯ 0.04 U (CI95%, 0.13 to 0.18 U); and BYNB, 0.21 Ϯ 0.06 U (CI95%, 0.18 to 0.25 U). Growth in all media was statistically greater with the agitated counterparts (P Ͻ 0.0001). The best growth was obtained with BYNB (mean Ϯ SD at 48 h, 0.77 Ϯ 0.07; CI95%, 0.73 to 0.81). In RPMI 1640 with or without glucose the final growths reached were similar (in RPMI 1640, the mean Ϯ SD at 48 h was 0.41 Ϯ 0.09 U and the CI95% was 0.36 to 0.46 U; in RPMI-2% glucose, the mean Ϯ SD at 48 h was 0.43 Ϯ 0.08 U and the CI95% was 0.38 to 0.47 U; P ϭ 0.623), though the lag phase in RPMI 1640 was shorter than that in RPMI-2% glucose (lag phase, 7.6 Ϯ 1. Fig. 2 . In this figure, each inhibition curve is the mean of the seven MIC determinations. As stated above, agitated BYNB showed the best growth and also the best inhibitory curve, followed by agitated RPMI-2% glucose. In both media the endpoint determination could be performed objectively. The inhibitory curves produced by the NCCLS M27A methodology (with or without agitation), static RPMI-2% glucose, and static BYNB were very difficult to interpret due to the gentle slope of the curve. Therefore, the identification of a MIC endpoint could not be performed with C. neoformans growing under static antifungal susceptibility testing conditions. Only the MICs obtained with shaken microplates are shown in Table 2 . As stated above, some strains grew poorly following NCCLS M27A methodology, so that their MICs could not be calculated. None of the three methods allowed a distinction to be made between strains as putatively susceptible or resistant to amphotericin B based on clinical outcome. For flucytosine and fluconazole, wider MIC ranges were observed with BYNB (Table 2) .
(iv) MICs for QC strains. The NCCLS M27A document recommends a visual endpoint for the microdilution method (4). Thus, the MIC of amphotericin B is defined as the lowest concentration exhibiting a complete inhibition of growth. The MICs of flucytosine and the azoles are defined as the lowest concentrations at which a prominent decrease in turbidity is detected (4) . Furthermore, the MIC ranges for QC strains were determined by the macrodilution method (4) . Despite this fact, we have compared the results obtained by the spectrophotometric determination of the MICs with the reference range obtained by the NCCLS M27A method (4). The spectrophotometric MIC values obtained at 48 h are shown in Table 3 . For NCCLS M27A and RPMI-2% glucose methodologies, all MIC 50 s, static or shaken, of C. krusei ATCC 6258 were within the published range (4). With NCCLS M27A methodology and C. parapsilosis only the MIC 80 s of shaking cultures were in the reference range (4) . For the QC strains, static or shaken, all amphotericin B MICs were within the published range (4) .
In summary, this work demonstrates that agitation plus a higher inoculum size is necessary for performing antifungal susceptibility testing of C. neoformans. The growth of C. neoformans in static cultures is very poor. Furthermore, susceptibility tests are generally designed to measure the antimicrobial activity under conditions yielding adequate growth; for C. neoformans, this means agitation of cultures. Thus, for future development of antifungal susceptibility testing inclusion of agitation during incubation, particularly with C. neoformans, should be considered. Our preliminary results suggest that RPMI or BYNB, an inoculum size of 10 4 or 10 5 CFU/ml, and agitation of microplates may be a starting point for this development.
